Tag: cybin
-
![MYND Life Sciences (MYND.C) provides unorthodox route to better mental health]()
MYND Life Sciences (MYND.C) provides unorthodox route to better mental health
We’re living in interesting times and I mean that in the Chinese curse kind of way. We can’t seem to stop to catch our breath when it comes to this pandemic, and the news sources we trust to keep us informed can’t seem to get the story straight. The result is more isolation, frustration, and…
-
![The top 10 most cashed up psychedelics companies right now]()
The top 10 most cashed up psychedelics companies right now
“In business, cash is oxygen” – Gary Vaynerchuk Psychedelics is a cash-intensive business. Earlier in the week, I wrote about how clinical trials alone cost companies tens, sometimes hundreds of millions of dollars. And that’s only part of the picture. According to Tufts Center for the Study of Drug Development, bringing a new FDA-approved drug…
-
![Psyched for this weeks news from CYBN.NE, PSYC.C, MNMD.Q, MSET.C, FTRP.Q, MYCO.NE, RVV.C, FH.NE, CMND.C, ATAI.Q]()
Psyched for this weeks news from CYBN.NE, PSYC.C, MNMD.Q, MSET.C, FTRP.Q, MYCO.NE, RVV.C, FH.NE, CMND.C, ATAI.Q
This week, news from the psychedelic sector has been dominated by patent applications and earnings being released. Here’s the run down of this week’s news. Cybin (CYBN.NE) It’s been a busy week for Cybin. Last week, after market close, they released their financials for the quarter ending on June 30, 2021, which showed they had…
-
![Cybin (CYBN.NE) gets final approval to list on NYSE American and announces public offering]()
Cybin (CYBN.NE) gets final approval to list on NYSE American and announces public offering
Cybin (CYBN.NE) announced that they have received final approval from the New York Stock Exchange (NYSE) to list its shares on the NYSE American exchange. Beginning next Thursday, on August 5, 2021, Cybin will begin trading on the NYSE American under the ticker “CYBN”. Cybin will continue to trade on the NEO exchange, also under…
-
Cybin (CYBN.NEO): Grown up approach to psychedelics brings half billion valuation… so far
Back in January of this year, we told you about a psychedelics company that was going to come at that sector like many had talked about, but few had achieved. Their angle? Be a biotech company. Don’t dick about with fakey business plans or black velvet paintings of Elvis. No Jamaican B&Bs dressed up as…
-
While your Bitcoin and Dogecoin shredded, MARV, GMX, CYBN, GLM, GMTN, and PINK doubled: Diversify, children!
Who’s a boomer now, Dogetards? For a few months there, a legion of newly minted investors, convinced they invented daytrading with their stimulus cheques and chicken tendies, watched their $500 investments run to new heights, taking AMC Cinemas (AMC.Q) to a $28 billion valuation, and driving Bitcoin and Dogecoin to stupid new highs. It was…
-
![Cybin (CYBN.E) new tryptamine patent improves outcome quality]()
Cybin (CYBN.E) new tryptamine patent improves outcome quality
Cybin (CYBN.E) filed a new provisional patent application for its ongoing drug candidate programs today, according to a press release. The application includes compositions which the company anticipates will improve pharmacokinetic profiles while keeping efficacy measures of the original molecules. The company’s patent also offers new delivery systems to increase onset of Cybin’s psychedelic tryptamine,…
-
![I am anecdotal evidence for Cybin’s (CYBN.NE) plan to target alcoholism with mushrooms]()
I am anecdotal evidence for Cybin’s (CYBN.NE) plan to target alcoholism with mushrooms
Last week Cybin (CYBN.NE) announced it was targetting alcoholism with its novel psychedelic compound CYB003. Another EG staffer wrote a piece last Monday outlining the details of the plan, but I’m going full editorial for this one as I have some experience with the topic. Through a series of psychedelic trips in my teen years,…
-
![Cybin (CYBN.NE) demonstrates Proof of Concept on CYB003 and CYB004 psychedelic molecules]()
Cybin (CYBN.NE) demonstrates Proof of Concept on CYB003 and CYB004 psychedelic molecules
Cybin (CYBN.NE) announced that they have successfully demonstrated Proof of Concept for their deuterated tryptamine programs, CYB003 and CYB004. The Proof of Concept revolves around the duration of psilocybin. A normal psilocybin experience will last around six hours, and can take up to an hour to begin. However, in their press release, Cybin notes that…
-
![Cybin (CYBN.NE) establishes Clinical Advisory Board as they gear up for trials]()
Cybin (CYBN.NE) establishes Clinical Advisory Board as they gear up for trials
Cybin (CYBN.NE) announced they are forming a Clinical Advisory Board, which will be chaired by Alex Belser, Cybin’s Chief Clinical Officer. The board will consist of Belser (PhD), Maurizio Fava (MD), Lynn Marie Morski (DM) and Anthony Back (MD). All members of the board have professional experience in either medicine or research. Fava, the Psychiatrist-in-Chief…
